All News
What is IPAF?
Idiopathic Interstitial Pneumonia with Autoimmune Features - or IPAF - describes patients with interstitial pneumonia with autoimmune features, but they don’t meet a diagnosis of a CTD.
Read Article
Polypharmacy Impairs Rheumatoid Arthritis Outcomes
A French early rheumatoid arthritis (RA) study has shown that polypharmacy (PP) was associated with significant lower treatment responses and more serious adverse events (SAEs).
Malignancies Not Increased with Biologic Therapies
The risk of malignancy in rheumatoid arthritis (RA) patients receiving biologic agents was evaluated by metanalysis of randomized controlled trials (RCTs) and found no significant increased risk of malignancy compared with other disease-modifying antirheumatic drugs (DMARDs) or with placebo.
Read Article
Rheumatoid arthritis begins long before symptoms
d
EurekAlert!
Scientists have discovered that rheumatoid arthritis (RA) doesn’t start when the pain begins. It silently starts years earlier.The new research reveals that people at risk for RA experience dramatic immune system changes long before they feel symptoms.
Read Article
ILD and ANCA: What to do?
Several cohort studies conducted in Asia, Europe and the Americas have evaluated the clinical significance of antineutrophil cytoplasmic antibodies (ANCA) when detected in patients with interstitial lung disease (ILD) as well as the types of ILD encountered in patients with microscopic polyangiitis (MPA) and their effect on the prognosis of MPA.
Read Article
CAR-T Product Shows Early Promise in Lupus
Five patients with systemic lupus erythematosus (SLE) in China have been treated with a potentially groundbreaking form of chimeric antigen receptor (CAR) T-cell therapy, researchers reported, with encouraging results after 3 months. https://t.co/eg37PZK6kn
Dr. John Cush RheumNow ( View Tweet)
PPP syndrome = a rare triad
👉 Pancreatitis + Polyarthritis + Panniculitis
🔬 Pathogenesis: circulating pancreatic enzymes (esp. trypsin) → fat necrosis in subcutis & bone marrow.
📌 Clue: painful nodules + arthritis, often with minimal abdominal symptoms.
#Rheumatology https://t.co/3qniCmahgl
ILLIASUL IBAD IlliasulK ( View Tweet)
Inception SLE study of 674 pts (without LN), mean age 34 yrs - 154 (23%) developed new proteinuria (LN) after median of 3.6 yr. Cumulative antimalarial exposure did NOT lower risk of LN (HR 0.98; 0.94-1.02); same for those w/ serologically active SLE (HR 0.97) https://t.co/8OU3yJAvhN
Dr. John Cush RheumNow ( View Tweet)
OL study of 60 pts w/ new idiopathic retroperitoneal fibrosis (GFR >30) Rx w/ low dose MTX+pred VS Pred only. @ 9 mos remission: 90% MTX+Pred vs 81% Pred (noninferior). Time-to-remission, RPF thickness & relapses were same; but pred use was lower w/ MTX+pred (p < 0.001) https://t.co/13cjnl4Ke4
Dr. John Cush RheumNow ( View Tweet)
Turkish study of 799 psoriasis pts - 30% had concurrent onset PsO & PsA & in 70% there was a long transition time (~13 yrs) from PsO-to-PsA. Factors assoc w/ prolonged interval included Depression, fatigue, scalp PsO(OR 7), nail PsO (3.2), +Fhx & enthesitis ever (OR 2) https://t.co/wqtSbeQ2vz
Dr. John Cush RheumNow ( View Tweet)
Canakinumab in VEXAS - 47 males Rx w/ anakinra (44), canakinumab (9), or both(6). Response @1 mos: ANAK 34% vs CANK 100%; 22% vs 78% @ 3 mos. Drug survival was 54 mos CANK 300/m; 7 mo CANK 150/m; 1 mo ANAK. More ISR (47% v 0) & infx w/ ANAK https://t.co/Y3iSfajTal https://t.co/qTNamGDwVI
Dr. John Cush RheumNow ( View Tweet)
Prospective French study of 101 RA-ILD (mean 66yrs) assessed for shorter WBC telomere length (LTL); short LTL seen in 43% & assoc w/ lower FVC (82% vs 93%pred) & TLCO (49% vs 63%) & greater FVC/DLCO decline & lung progression after 12 mos (47% vs 22%; p<0.001) https://t.co/ObVeon0riy
Dr. John Cush RheumNow ( View Tweet)
Monthly survey - 351 ArthritisPower #RA Registry pts reported 523 nonserious infxns (31% ; most URI), few resulted in ED or hospitalization. But NSIA led to missed work (37%) or RA Rx interruptions (26%) and more fatigue. NSIE may contribute to more disease flares https://t.co/Al5B5oxvFg
Dr. John Cush RheumNow ( View Tweet)
DERM on RheumNow Podcast (September 2025)
Content curated for dermatologists and skin deep HCPs – on Psoriasis, CLE, vasculitis, HS and dermatology drugs use, efficacy and side effects and more.
https://t.co/zZpheX1epS https://t.co/uOd9Gy0V2E
Dr. John Cush RheumNow ( View Tweet)
QD Clinic: Stick or twist (when not to change treatment
Dr. Richard Conway, Dublin, discusses a case about when not to change treatment, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025.
https://t.co/kUopZ1bpVi https://t.co/mt0tKcQzKQ
Dr. John Cush RheumNow ( View Tweet)
Assessing ILD in Rheumatology
Janet Pope, MD, shares practical insights on how rheumatologists should assess ILD in their patients. Sponsored By: Boehringer Ingelheim
https://t.co/Mxg9P50m7C
#ILD #Rheumatology https://t.co/aAuxbJBxBn
Dr. John Cush RheumNow ( View Tweet)
Scleroderma-associated Interstitial Lung Disease
Since the first placebo-controlled randomized trial published nearly 20 years ago for the treatment of patients with SSc-ILD, evaluating cyclophosphamide vs. placebo, there have been several other randomized studies to guide the https://t.co/Dh7XpP6qhF
Dr. John Cush RheumNow ( View Tweet)
Panel of IPF assoc 8 biomarkers (eotaxin, Flt-3L, IL-8, MDC, MCP-1, MMP-2/7/9) tested in 2 RA-ILD cohorts (n 164). IPF multibiomarker scores higher in RA-ILF vs RA alone. Highest quartile had ~2 fold incr risk of prevalent & incident ILD https://t.co/vYg9iB4EtH https://t.co/5ZZx6gg7A4
Dr. John Cush RheumNow ( View Tweet)
Big Fat FDA Pink Slip (9.19.2025)
Dr. Jack Cush reviews the news and journal reports from this week on RheumNow. Today we cover GLP-1 agonists, acupuncture, what JAKs won’t do & an FDA Pink Slip.
https://t.co/Za39hxI8Qf https://t.co/yN4K9tOuTt
Dr. John Cush RheumNow ( View Tweet)
Should we be "scoring" comorbidity to predict outcomes? SLE metanalysis looked at Charlson Comorbidity index (CCI). 3 RCTs, 1175 SLE pts show higher CCI scores predicts increased all-cause mortality (OR 3.92(95% CI: 2.74–5.60) https://t.co/LXfsGo9iJq https://t.co/eK31lnFrJk
Dr. John Cush RheumNow ( View Tweet)
